NFKB1 and cancer: Previous pre-clinical and clinical observations have suggested that Hsp90 inhibitors may be most effective when used as ‘chemomodulators’, exploiting their reported capacity to reduce NF-κB activity to sensitise metastatic cancer cells to chemotherapeutic and biological agents such as oxaliplatin and TRAIL (Rakitina et al, 2003).